EpiVax Enhances Technology Leadership with the Appointment of Guilhem Richard

EpiVax Strengthens Its Technological Leadership Amidst Key Innovations

EpiVax, Inc., a prominent player in the immunoinformatics field, has recently made headlines with the appointment of Dr. Guilhem Richard as their new Chief Technology Officer (CTO). With a robust background in bioinformatics, Dr. Richard has been part of the EpiVax team since 2014, playing a pivotal role in developing the Ancer® platform for personalized cancer vaccines. His expertise and vision are expected to guide EpiVax through its next phase of innovation.

A New Chapter in Leadership

Dr. Richard’s promotion is a significant milestone for EpiVax, aligning with several strategic advancements in their technological offerings. His leadership comes at a time when the company has reported major updates that leverage state-of-the-art artificial intelligence (AI) and machine learning (ML) techniques. These enhancements promise to boost the capabilities of EpiVax's ISPRI platform, which is essential for evaluating the immunogenicity of biological therapies.

The company’s recent developments have resulted in substantial improvements in predictive accuracy for their JanusMatrix model, enhancing its performance by 50%. Furthermore, new immunogenicity models that predict anti-drug antibody (ADA) rates for monoclonal therapies have demonstrated a remarkable sixfold increase in the correlation between predicted and observed outcomes, while also achieving an 85% reduction in false negatives. These predictive tools are set to be available on the ISPRI platform soon, offering valuable services for global biotech and pharmaceutical partners.

Regulatory Milestones

In addition to technological advancements, EpiVax has made significant strides in compliance with regulatory standards. The company has submitted a new Master Model File (MMF) for its PANDA® in silico model to the FDA. This submission supports the expedited regulatory process for abbreviated new drug applications (ANDAs) concerning generic peptide drugs. The MMF offers comprehensive descriptions of immunogenicity evaluation methodologies, streamlining the submission process for sponsors and facilitating FDA reviews.

The accessibility of the MMF PANDA® represents a critical step forward, ensuring a more efficient pathway for drug manufacturers to reference EpiVax’s methodologies in their regulatory submissions, thereby expediting the preparation and review of ANDA packages.

Future Innovations and Enhancements

EpiVax’s commitment to innovation remains strong, with plans for further enhancements to the ISPRI platform. An upcoming version of EpiMatrix® is expected to refine predictive capabilities, and redesigned user interfaces could significantly enhance user experience. These improvements aim to empower partners to strengthen their product portfolios effectively.

About EpiVax

As a leader in preclinical immunogenicity assessment and peptide therapy optimization, EpiVax collaborates extensively with global companies, academia, and agencies to accelerate the evaluation of immunogenicity risks, immune modulation, and rapid vaccine design. The company's innovative approaches and tools are pivotal in ensuring the success of therapeutic developments in a rapidly evolving landscape.

For further information, contact Sarah Moniz, Business Development Director at EpiVax, via email at [email protected].